Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine

INTRODUCTION: Onabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatment of chronic migraine (CM), a highly disabling disorder. Although treatment response varies among patients, current guidelines suggest to stop treatment after cycle 2 if no response is achieved. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarchielli, Paola, Romoli, Michele, Corbelli, Ilenia, Bernetti, Laura, Verzina, Angela, Brahimi, Elona, Eusebi, Paolo, Caproni, Stefano, Calabresi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723003/
https://www.ncbi.nlm.nih.gov/pubmed/29255444
http://dx.doi.org/10.3389/fneur.2017.00655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723003/
https://www.ncbi.nlm.nih.gov/pubmed/29255444
http://dx.doi.org/10.3389/fneur.2017.00655

Ejemplares similares